{"entity":{"id":"amt-707","kind":"drug","name":"CUSP06","aka":["AMT-707"],"tldr":"CUSP06 is an experimental antibody-drug conjugate from OnCusp Therapeutics, in phase 1 trials for platinum-resistant ovarian cancer, renal cell carcinoma and CDH6-positive solid tumours.","summary":"CUSP06 (AMT-707) is an antibody-drug conjugate from OnCusp Therapeutics, with Multitude Therapeutics as licensor (retains Greater China rights). A cadherin-6 (CDH6)-directed antibody-drug conjugate: a CDH6-binding antibody joined by a protease-cleavable linker to an exatecan payload, a topoisomerase-1 inhibitor, with a drug-to-antibody ratio of eight. Its furthest stage is phase 1, for platinum-resistant ovarian cancer, renal cell carcinoma and CDH6-positive solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1b portion of a phase 1 study; NCT06234423 recruiting on the registry (checked 3 Nov 2026). FDA Fast Track in platinum-resistant ovarian cancer per the October 2026 release. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"OnCusp Therapeutics: oncusptx.com","url":"https://www.oncusptx.com/rd/index.html"},{"label":"OnCusp Therapeutics: oncusptx.com","url":"https://www.oncusptx.com/html/companynews/118.html"},{"label":"OnCusp Therapeutics: oncusptx.com","url":"https://www.oncusptx.com/html/companynews/118.html"},{"label":"OnCusp Therapeutics: flcube.com","url":"https://flcube.com/?p=30798"},{"label":"ClinicalTrials.gov: trials of AMT-707","url":"https://clinicaltrials.gov/search?intr=AMT-707"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["platinum-resistant-ovarian-cancer","metastatic-cancer"],"sections":[],"technologies":[],"targets":["cdh6"],"drugs":[],"companies":["oncusp-therapeutics","multitude-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06234423"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AMT-707","modality":"Antibody-drug conjugate","mechanism":"A cadherin-6 (CDH6)-directed antibody-drug conjugate: a CDH6-binding antibody joined by a protease-cleavable linker to an exatecan payload, a topoisomerase-1 inhibitor, with a drug-to-antibody ratio of eight.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/amt-707/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"target":[{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/"}],"company":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/"},{"id":"oncusp-therapeutics","kind":"company","name":"OnCusp Therapeutics","route":"/companies/oncusp-therapeutics/"}],"trial":[{"id":"nct06234423","kind":"trial","name":"A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06234423/"}]}}